Build · Iktos
Iktos AI de novo design applied to select Pfizer small-molecule discovery programs (2021
Iktos AI de novo design applied to select Pfizer small-molecule discovery programs (2021
Iktos is a generative-AI drug-design company whose de novo molecule-design platform is used directly by partner pharma companies' medicinal chemists.
This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.
Source
Published by Iktos on its own site — read the original case study on iktos.ai ↗
Note: 404 not found; source URL (iktos.ai/resources/news/) is a broken/generic listing page. Checked the live news/articles/resources listings on iktos.ai — no article mentioning Pfizer was found.
More like this
Related use cases
- 01Integrated drug-discovery collaboration (Jan 2026
- 02Iktos announces Strategic Collaboration with Servier
- 03Iktos announces strategic collaboration with Cube biotech
- 04Iktos and Elsevier announce their partnership
- 05Collaboration: Iktos and Italfarmaco
- 06Additional AI-for-new-drug-design collaboration (Nov 2020